Article successfully added.

CyFlow™ CD266 Purified

CyFlow™ CD266 Purified
Alternative Name: Fn14, TNFRSF12A, TWEAK R
Antibody: Yes
Antigen: CD266
Application: Flow cytometry, Functional assays, Immunohistochemistry (frozen sections), Western blot
Clonality: monoclonal
Clone: ITEM-4
Field of Interest: Apoptosis, Immunophenotyping
Format/Fluorochrome: Purified
Isotype: IgG2b
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human, Mouse
Product number: AZ756227

For Research Use Only

$120.00 USD*

Price excludes any applicable taxes plus shipping costs

Description Documentation TDS & SDS
Description
Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg Volume 0.1 mL... more
Close menu
CyFlow™ CD266 Purified
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1 mL
ImmunogenHuman CD266-transfected P815 cells
Background InformationCD266 (TWEAK R, TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14), is a receptor for CD255 (TWEAK), the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor‑inducible 14 mediates multiple pathways of TWEAK‑induced cell death. J Immunol. 2003 Jan 1; 170(1):341‑8. < PMID: 12496418 > | Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H: Soluble and transmembrane TNF‑like weak inducer of apoptosis differentially activate the classical and noncanonical NF‑kappa B pathway. J Immunol. 2010 Aug 1; 185(3):1593‑605. < PMID: 20610643 > | Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan; 2(1):103‑108. < PMID: 22977477 > | Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A: Inflammatory cytokines and survival factors from serum modulate tweak‑induced apoptosis in PC‑3 prostate cancer cells. PLoS One. 2012; 7(10):e47440. < PMID: 23077618 >

TDS & SDS
Close menu

Technical Data Sheet

Safety Data Sheet